Laddar...
Bifeprunox versus placebo for schizophrenia
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long‐term symptoms of schizop...
Sparad:
| I publikationen: | Cochrane Database Syst Rev |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley & Sons, Ltd
2016
|
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457956/ https://ncbi.nlm.nih.gov/pubmed/27732740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012029.pub2 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|